The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Experts Discuss Unique Challenges Posed by Difficult-to-Treat RA

Experts Discuss Unique Challenges Posed by Difficult-to-Treat RA

November 24, 2020 • By Vanessa Caceres

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Dr. Smolen photo

Dr. Smolen.

ACR CONVERGENCE 2020—Patients with rheumatoid arthritis (RA) and concurrent liver disease or interstitial lung disease (ILD), or with treatment-refractory RA, pose treatment challenges, said panelists in the ACR Convergence 2020 session, How I Treat Difficult RA. Each panelist discussed a difficult case and raised big-picture questions on how to best treat patients facing each challenge.

You Might Also Like
  • RA Patients with ILD & Liver Disease Present Treatment Challenges
  • Osteoporosis Experts Discuss Bisphosphonate Holidays
  • COVID-19, New Research & More: 2 Experts Discuss Scientific Advances in Rheumatology at ACR Convergence 2020
Also By This Author
  • Online Medical Information Adds New Dimension to Patients’ Discussions with Doctors

RA & Interstitial Lung Disease

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

More data are needed to definitively choose the best treatment for RA and ILD, said Joan M. Bathon, MD, professor of medicine and chief of the Division of Rheumatology, Columbia University College of Physicians and Surgeons, New York City. In her talk, Dr. Bathon presented the case of a 65-year-old man found to have RA-ILD, as well as probable heart failure. She used the case as a springboard for treatment questions for combined RA-ILD.

Dr. Bathon reviewed treatment questions that arise with combined RA-ILD, which occurs in about 8% to 15% of RA patients. The condition has significant mortality, with a median survival of 2.5 years. In one study she shared, about 25% of those with RA-ILD died in the first year after diagnosis.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

One question is whether methotrexate and leflunomide increase the risk for ILD. Study findings with methotrexate have mixed results, and not many studies focused on this for leflunomide. Overall though, these common RA therapies don’t appear to increase the risk for ILD, Dr. Bathon said.

As to whether a disease-modifying anti-rheumatic drug (DMARD) that can be used both for arthritis and ILD exists, the answer is maybe, Dr. Bathon said. She said that, so far, results for tumor necrosis factor inhibitors have been controversial and open-label studies with abatacept suggested a lack of worsening after starting the treatment for RA-ILD. A trial called FaSScinate, which investigated tocilizumab for systemic sclerosis, found less worsening of disease in the tocilizumab-treated group.2,3 Still, this is another question for which more data and studies are needed, she added.

When discussing whether such antifibrotics as nintedanib or pirfenidone would be more efficacious than a DMARD for RA-ILD, Dr. Bathon pointed out that no direct comparison data exist. For the fibrotic subtype of ILD, she says nintedanib or perfinodone may be most appropriate to use as they target inhibiting growth factors. In clinical practice, Dr. Bathon said she relys on the preferences of the pulmonologist helping to treat her patients with RA-ILD.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Best Ways to Manage Refractory RA

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: ACR Convergence 2020, ACR Convergence 2020 – RA

You Might Also Like:
  • RA Patients with ILD & Liver Disease Present Treatment Challenges
  • Osteoporosis Experts Discuss Bisphosphonate Holidays
  • COVID-19, New Research & More: 2 Experts Discuss Scientific Advances in Rheumatology at ACR Convergence 2020
  • Inflammatory Myopathies Difficult to Diagnose, Treat

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.